Product Description
A methylated tryptophan with immune checkpoint inhibitory activity. Indoximod inhibits the enzyme indoleamine 2,3-dioxygenase (IDO), which degrades the essential amino acid tryptophan, and may increase or maintain tryptophan levels important to T cell function. Tryptophan depletion is associated with immunosuppression involving T cell arrest and anergy. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/indoximod)
Mechanisms of Action: IDO1 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Lumos Pharma
Company Location: AUSTIN TX 78756
Company CEO: Richard J. Hawkins
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Melanoma
Phase 2: Prostate Cancer|Breast Cancer|Melanoma|Male Breast Cancer|Ependymoma|Glioblastoma|Glioma|Medulloblastoma
Phase 1: Melanoma|Brain Cancer|Glioma|Ependymoma|Kidney Diseases|Breast Cancer|Oncology Solid Tumor Unspecified|Glioblastoma|Pancreatic Cancer|Lung Cancer|Gliosarcoma|Medulloblastoma|Non-Small-Cell Lung Cancer|Acute Myeloid Leukemia|Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| GCC2020 | P1 |
Recruiting |
Brain Cancer|Glioblastoma|Ependymoma|Medulloblastoma |
2026-08-01 |
|
| GCC1949 | P2 |
Recruiting |
Glioma|Glioblastoma|Medulloblastoma|Ependymoma |
2025-10-02 |
|
| 2014-003540-12 | P2 |
Terminated |
Breast Cancer |
2022-05-04 |
|
| 2017-003634-93 | P3 |
Unknown status |
Melanoma |
2021-11-28 |